

## Technology Advisory Interests Register

**Topic: Talquetamab for treating relapsed or refractory multiple myeloma after 3 treatments [ID5082]**

**Publication Date: TBC**

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Pedro Saramago Goncalves	TAC Committee Member	Financial	<p>I would like to declare that in the last 12 months I have worked with GSK (with a potential comparator for this technology appraisal) but in an unrelated indication, advanced ovarian cancer.</p> <p>I would like to declare that in the last 12 months I have worked with J&amp;J on a project evaluating US FDA Accelerated Approvals process i.e. non-technology specific.</p>	17/07/2025 24/09/2025	It was agreed that Pedro's declaration would not prevent them from participating in discussions on this appraisal
Mike Chambers	TAC Committee Member	Financial	I have attended an advisory panel for Pfizer (possible comparator mfr) in an unrelated disease area - prostate cancer.	17/07/2025 23/09/2025	It was agreed that Mike's declaration would not prevent them from participating in discussions on this appraisal
Kate Ren	TAC Committee Member	Financial	I provided statistical methodology consultancy service to a possible comparator company Pfizer for an unrelated treatment in an unrelated disease area (Tofacitinib for Moderate-to-Severe Ulcerative Colitis).	18/07/2025 23/09/2025	It was agreed that Kate's declaration would not prevent them from participating in discussions on this appraisal

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Jonathan Sive	TAC Committee Member	Financial	Sponsored by Johnson and Johnson to attend EHA meeting 2025. (No advisory board work) Exec committee member of UK Myeloma Society.	18/07/2025	It was agreed that Jonathan's declaration would not prevent them from participating in discussions on this appraisal
Prithwiraj Das	TAC Committee Member	Non-financial professional	I am currently engaged in helping one of the comparator manufacturers (GSK) in an unrelated indication.	25/07/2025	It was agreed that Prithwiraj's declaration would not prevent them from participating in discussions on this appraisal
			I work in life sciences, including pharmaceutical market access, as Founding Director of G2PR Ltd. I have not worked on these products/indications in the last 12+ months	29/09/2025	
Elizabeth Thurgar	TAC Committee Member	Financial	<ul style="list-style-type: none"> <li>- In the last 12 months I have worked with JNJ on teclistamab for MM</li> <li>- In the last 12 months I have worked with BMS in an unrelated indication, MDS</li> <li>- In the last 12 months I have worked with GSK in an unrelated indication, uUTI</li> <li>- In the last 12 months I have</li> </ul>	17/07/2025 23/09/2025	It was agreed that Elizabeth's declaration would prevent them from participating in discussions on this appraisal

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			worked with Pfizer, a listed comparator company, in an unrelated indication, non-small cell lung cancer.		
Satish Venkateshan	TAC Committee Member	Financial	Regeneron is developing livoseltamab a BCMAxCD3 bispecific in multiple myeloma. It is going through regulatory approval process in some of the countries already. Livoseltamab has been approved by EMA as monotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy. I work for Regeneron, pharmaceuticals/biotech company. I also own shares in the company and have stock options	18/07/2025 23/09/2025	It was agreed that Satish's declaration would prevent them from participating in discussions on this appraisal
Jon Tosh	TAC Committee Member	Financial	I am employed by GSK, who are a comparator company for this topic.	25/09/2025	It was agreed that Jon's declaration would prevent them from participating in

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
					discussions on this appraisal
Neil Rabin	Expert	Financial	<ul style="list-style-type: none"> <li>I have received payments from Janssen and Menarini Stemline for advisory boards, delivering educational meetings and to attend congresses.</li> <li>I have received payments from BMS, Pfizer and Sanofi for advisory boards and delivering educational meetings.</li> <li>I have received a payment from GSK for an advisory board.</li> <li>I am currently the Past Chair of the UK Myeloma Society (UKMS), and sit on the Executive Committee of the UKMS.</li> </ul>	17/03/2025 14/10/2025	It was agreed that Neil's declaration would not prevent them from providing expert advice to the committee
Sarah Lawless	Expert	Financial	<ul style="list-style-type: none"> <li>I have received payments from BMS/Celgene, BeOne and Pfizer for advisory boards.</li> <li>I have received payment from Johnson and Johnson, BeOne and AstraZeneca for Congress support.</li> <li>I have received speaker fees from Johnson and Johnson,</li> </ul>	16/03/2025 14/10/2025	It was agreed that Sarah's declaration would not prevent them from providing expert advice to the committee

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>BMS/Celgene, Sanofi, BeOne and AstraZeneca.</p> <ul style="list-style-type: none"> <li>I am a member of UK Myeloma Society and the Invited N. Ireland representative on executive committee.</li> <li>Belfast City Hospital is a site selected for the TALISMAN trial for which I am principal investigator. This trial is not yet open to recruitment. This is a phase II study A study to evaluate preventive treatments for talquetamab-related oral toxicity.</li> <li>Johnson and Johnson is a premium sponsor of the UK Myeloma Society which means they contribute £15,000 of funding per year to the society. This money is used to run our spring and autumn educational meetings and to provide bursaries that allow UKMS members to attend international meetings</li> </ul>		
Caroline Donoghue	Expert	Financial	<ul style="list-style-type: none"> <li>Myeloma UK has received funding from Johnson &amp; Johnson in the last 12 months. Funding is received</li> </ul>	03/03/2025 14/10/2025	It was agreed that Caroline's declaration would not prevent them

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>for a range of purposes and activities namely core grants, project specific work, and gifts, honoraria, or sponsorship.</p> <ul style="list-style-type: none"> <li>In 2024, 4% of Myeloma UK's income came from pharmaceutical companies including Johnson &amp; Johnson, BMS, GSK, Menarini Stemline, Pfizer and Sanofi.</li> </ul>		from providing expert advice to the committee